Applied Food Technologies

Applied BioCode Appoints Industry Veteran Beth Laderman as Chief Scientific Officer

Retrieved on: 
Thursday, September 28, 2023
Health, Infectious Diseases, Health Technology, Research, Science, Biotechnology, Applied Food Technologies, Bachelor, FDA, Patient, PCR, Nomenclature codes, CSO, Management

Applied BioCode announced today that Beth Laderman has been appointed as their new Chief Scientific Officer (CSO) signaling a significant step in the company’s expansion.

Key Points: 
  • Applied BioCode announced today that Beth Laderman has been appointed as their new Chief Scientific Officer (CSO) signaling a significant step in the company’s expansion.
  • Dr. Laderman joins as Applied BioCode continues to expand its US commercial footprint and explores US & global expansion and new opportunities for their technology.
  • “I’m excited to be joining Applied BioCode and for the opportunity to support its mission to bring comprehensive, affordable, high throughput multiplex testing to all patients,” said Beth Laderman, incoming chief science officer for Applied BioCode.
  • To learn more about the Applied BioCode team and offerings, visit: https://www.apbiocode.com/products/

Applied UV Retains Quantiva™ to Integrate AI and Machine Learning Capabilities into Its PURONet™ and Airocide™ Systems

Retrieved on: 
Thursday, June 15, 2023
Food, United Nations, University, Atmosphere, Food preservation, Applied Food Technologies, Whole Foods Market, Volatile organic compound, Pollen, Vegetable, FAO, Crop, Food and Agriculture Organization Corporate Statistical Database, NASA, Collection, Machine learning, Food chain, Logic, Artificial intelligence, Bacteria, Transport, Food security, Virus, Jan Vansina, Allergen, Agriculture

MOUNT VERNON, NY , June 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Applied UV, Inc. (Nasdaq: AUVI) (“Applied UV” or the  “Company”), a leading provider of advanced food security and air and surface disinfection technology, has engaged Quantiva™, a provider of AI-driven consulting and software engineering services and solutions, to support the further development and expansion of the Company’s proprietary indoor air quality monitoring software, PURONet™.

Key Points: 
  • The Airocide™ proprietary technology eliminates airborne pathogens including bacteria, viruses, pollen, mold, yeast, allergens, VOCs, and odors and is known globally for its ability to remove ethylene by utilizing Photo-catalytic Oxidation.
  • It is currently used extensively in the post-harvest food preservation supply-chain with global end users such as Delmonte, Whole Foods and Esmerelda Farms to name a few.
  • The opportunity to address this global post-harvest problem is at the very core of our values, improving societal outcomes.
  • Moreover, a staggering 31.15% of all fruits and vegetables are lost globally due to high perishability and a lack of adequate intervention strategies.

Applied BioCode Announces Distribution Agreement with Medline Industries

Retrieved on: 
Monday, May 8, 2023
Infectious Diseases, Biotechnology, Hospitals, Health, EUA, Hair, Bachelor, BMB, Allergy, RPP, Medline Industries, SARS-CoV-2, COVID-19, Infection, CE marking, Applied Food Technologies, MEDLINE, Nomenclature codes, Lower respiratory tract infection, Immunochemistry, Emergency Use Authorization, Federal Food, Drug, and Cosmetic Act, Hospital, RSV, Analyte-specific reagent, Laboratory, Autoimmune disease, Molecular Probes, LDT, IVD, Diagnosis, GPP, FDA, Virus, Pharmaceutical industry, Vaccine

Applied BioCode today announced an agreement with Medline Industries, a leading manufacturer and distributor of healthcare products, to distribute the MDx-3000 System and its comprehensive menu.

Key Points: 
  • Applied BioCode today announced an agreement with Medline Industries, a leading manufacturer and distributor of healthcare products, to distribute the MDx-3000 System and its comprehensive menu.
  • Under the terms of the distribution agreement, Medline will offer the MDx-3000 System to clinical laboratory customers across the U.S.
    “Applied BioCode is thrilled to partner with Medline Industries, and we look forward to continuing our expansion into hospitals and reference laboratories in the U.S.,” said Chris Bernard, CEO of Applied BioCode.
  • For more information on the Applied BioCode’s platform and products, visit: https://apbiocode.com/products.htm
    Applied BioCode is an IVD manufacturer that designs, develops, and commercializes multiplex testing products.
  • Applied BioCode, Inc. has also been granted an Emergency Use Authorization (EUA) from the U.S. FDA for its BioCode® SARS-CoV-2 Flu Plus Assay ⱡ, BioCode® SARS-CoV-2 Assay*, and an additional EUA for Pooled COVID-19 Testing*.

Applied DNA's CertainT® Supply Chain Traceability Platform Featured in New York Times Article About the Need for Transparency and Compliance in Global Supply Chains Under Recently Passed U.S. Federal Regulation

Retrieved on: 
Friday, April 7, 2023
Agriculture, Natural Resources, White House, Federal Government, Publishing, Textiles, Media, Packaging, Communications, Chemicals, Plastics, Homeland Security, Logistics, Supply Chain Management, Manufacturing, Transport, Public Policy, Government, Other Science, Pharmaceutical, Technology, Genetics, Security, Retail, Science, Biotechnology, Nanotechnology, Medical Supplies, Health, Artificial Intelligence, DNA, The New York Times, XUAR, Oxygen, A.I, Applied Food Technologies, Temperature, Carbon, Republic, Soil, Map, U.S. Department of Defense Strategy for Operating in Cyberspace, Uyghur Forced Labor Prevention Act, Plan, UFLPA, Textile, Isotope, PCR, Mysteries, Vaccine

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in PCR-based DNA technologies, announced that its CertainT® supply chain traceability platform is featured in an article on the home page of the New York Times website today.

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in PCR-based DNA technologies, announced that its CertainT® supply chain traceability platform is featured in an article on the home page of the New York Times website today.
  • The article, titled "How A.I.
  • and DNA Are Unlocking the Mysteries of Global Supply Chains," centers on the mounting need for the textile and other industries to employ tracing technologies to ensure compliance with the Uyghur Forced Labor Prevention Act (UFLPA).
  • CertainT is a multi-layered forensic authentication system that employs an integrated "tag-test-track" approach to maximize supply chain security and minimize counterfeiting, including verifying cotton's geographic region of origin.

Applied DNA Announces Receipt of Largest Single Purchase Order for LinearDNA™ To-Date

Retrieved on: 
Monday, October 10, 2022
Health, Stem Cells, Genetics, Research, Science, Pharmaceutical, Biotechnology, NYSDOH, Lists of diseases, LinkedIn, Drug Quality and Security Act, SEC, New York State Department of Health, Diagnosis, Annual report, NASDAQ, Biotechnology, RNA, Twitter, Research, Applied DNA Sciences, IVT, Securities Act of 1933, History, PCR, Private Securities Litigation Reform Act, Infection, Company, Cancer, Industry, CEO, Securities Exchange Act of 1934, Bacteria, Forward-looking statement, DNA, FDA, Vaccine, Applied Food Technologies

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the Company), a leader in PCR-based DNA technologies, announced today that it received its largest single purchase order for LinearDNA valued above the mid-six-figures.

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) (the Company), a leader in PCR-based DNA technologies, announced today that it received its largest single purchase order for LinearDNA valued above the mid-six-figures.
  • LinearDNA is produced using an enzymatic (cell-free) manufacturing platform that eliminates the use of fermenters and bacteria required by plasmid DNA, the industrys current manufacturing standard for DNA.
  • LinearDNA eliminates many of the challenges associated with current plasmid-based DNA manufacturing and produces a DNA product without the risks of bacterial contamination and non-target DNA sequences.
  • Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid (DNA).

Applied DNA and the Cornell University College of Veterinary Medicine Announce Research Collaboration to Accelerate Application of LinearDNA™ Platform for Veterinary Health Applications

Retrieved on: 
Thursday, September 8, 2022
Veterinary, Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, University, Health, Science, Education, United States Department of State, Partnership, COVID-19, CEO, Securities Exchange Act of 1934, Securities Act of 1933, Veterinary medicine, Research, Applied DNA Sciences, Polymerase chain reaction, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, Associate, Medicine, Mouse, Infection, United States Department of Agriculture, Drug Quality and Security Act, USDA, Food, Agreement, LinkedIn, DNA, SEC, Cornell University College of Veterinary Medicine, PCR, Company, FDA, Biotechnology, History, Twitter, Clinical trial, Annual report, Private Securities Litigation Reform Act, Drug development, Health, Forward-looking statement, Vaccine, Applied Food Technologies, LNP, Virology

Recently , Applied DNA announced the successful administration and expression of a lipid nanoparticle-encapsulated (LNP) LinearDNA construct in mice via routine intramuscular (IM) injection.

Key Points: 
  • Recently , Applied DNA announced the successful administration and expression of a lipid nanoparticle-encapsulated (LNP) LinearDNA construct in mice via routine intramuscular (IM) injection.
  • Veterinary DNA vaccines present an attractive opportunity for us, and these animal studies should generate additional key validation data for our platform relevant to veterinary health.
  • Dr. Diel said, Vaccinology research and clinical trials are crucial to developing new prevention strategies that could have transformative applications in animal health.
  • Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid (DNA).

Applied DNA Launches Monkeypox Testing Service

Retrieved on: 
Tuesday, September 6, 2022
Managed Care, Research, General Health, Pharmaceutical, Infectious Diseases, Hospitals, Genetics, Science, Biotechnology, Medical Supplies, Practice Management, Health, Other Science, COVID-19, CEO, Securities Exchange Act of 1934, Securities Act of 1933, Research, Applied DNA Sciences, Monkeypox virus, CLEP, NASDAQ, Laboratory developed test, New York State Department of Health, LinkedIn, DNA, SEC, Infection, PCR, Monkeypox, LDT, FDA, Biotechnology, History, Attention, Certification, LLC, Twitter, NYSDOH, Annual report, Private Securities Litigation Reform Act, TAT, CDC, Forward-looking statement, Vaccine, Applied Food Technologies

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has launched monkeypox testing as a clinical reference laboratory testing service available to hospital systems and clinical labs located in New York State and in states that recognize New York's CLEP/CLIA certification for testing.

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has launched monkeypox testing as a clinical reference laboratory testing service available to hospital systems and clinical labs located in New York State and in states that recognize New York's CLEP/CLIA certification for testing.
  • Having built ADCLs stellar reputation for high-capacity, PCR-based COVID-19 testing with rapid TAT, we believe we can bring to bear the same expertise to the monkeypox public health emergency, stated Dr. James A. Hayward, president and CEO of Applied DNA Sciences.
  • ADCLs monkeypox test utilizes an A17L gene-target specific to monkeypox virus Clade II that enables the qualitative detection and differentiation of the monkeypox virus from other non-variola orthopoxviruses using real-time PCR.
  • To learn more about ADCLs monkeypox testing service, click to: adnas.com/monkeypox-testing
    Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid (DNA).

Virus Geeks, a Biotechnology Company, Becomes the First to Validate a Nasal Swab for Monkeypox, Covid-19, Influenza A&B All in One Swab

Retrieved on: 
Friday, September 2, 2022
Monkeypox, Technology, Safety, SAN, Awareness, Monkeypox virus, RT, Applied Food Technologies, Infection, National Association Medical Staff Services, Diagnosis, Quality of life, Organization, GLOBE, Company, Compliance, Risk, COVID-19, Health, Patient, Vaccine

Virus Geeks affiliated lab validated ANDiS Monkeypox virus nucleic acid detection kit for the purpose of the qualitative detection of the Monkeypox virus on the Applied Biosystems QuantStudio 5 Real-Time PCR instrument.

Key Points: 
  • Virus Geeks affiliated lab validated ANDiS Monkeypox virus nucleic acid detection kit for the purpose of the qualitative detection of the Monkeypox virus on the Applied Biosystems QuantStudio 5 Real-Time PCR instrument.
  • The ANDiS Monkeypox virus nucleic acid detection kit is a molecular test that aids in the diagnosis of the Monkeypox virus and is based on widely used nucleic acid amplification technology.
  • As the flu season approaches, Virus Geeks continues to stay ahead of the curve by making testing seamless with this solution of a single swab product.
  • To learn more about this and innovative solutions from Virus Geeks, visit the website at www.virusgeeks.com or contact customer service at 1-800-731-8815.

Applied DNA Submits PCR-based Monkeypox Virus Diagnostic Test for Approval to New York State Department of Health

Retrieved on: 
Friday, August 19, 2022
Research, Medical Supplies, Infectious Diseases, Biometrics, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, COVID-19, CEO, Securities Exchange Act of 1934, Securities Act of 1933, Research, Applied DNA Sciences, Monkeypox virus, NASDAQ, Infection, New York State Department of Health, Drug Quality and Security Act, LinkedIn, DNA, SEC, PCR, COVID-19 testing, New Yorkers, LDT, FDA, Biotechnology, Population, History, Twitter, LLC, NYSDOH, Annual report, Private Securities Litigation Reform Act, Forward-looking statement, Vaccine, Applied Food Technologies

Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC ("ADCL"), has submitted to the New York State Department of Health (NYSDOH) a validation package for its Company-developed monkeypox virus test in support of a request for full approval as a form of NYSDOH Laboratory Developed Test (LDT).

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC ("ADCL"), has submitted to the New York State Department of Health (NYSDOH) a validation package for its Company-developed monkeypox virus test in support of a request for full approval as a form of NYSDOH Laboratory Developed Test (LDT).
  • The PCR-based diagnostic is designed to identify the genetic signature of the Clade II variant of the monkeypox virus that is currently prevalent in the U.S.
  • Named the Linea Monkeypox Virus 1.0 Assay, the test would be ADCL's second successful LDT in less than one year if approved by the NYSDOH.
  • Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA").

Applied DNA Awarded Extension of Health Services Contract with The City University of New York 

Retrieved on: 
Tuesday, August 9, 2022
Biotechnology, Health Technology, Health, COVID-19, FDA, CUNY, Drug Quality and Security Act, Documentation, Health, Omicron, CEO, Forward-looking statement, Private Securities Litigation Reform Act, Applied DNA Sciences, EUA, SEC, Policy, Securities Exchange Act of 1934, City University of New York, LLC, Research, History, Annual report, NYSDOH, CDC, DNA, RT-PCR, COVID-19, Twitter, Partnership, New York State Department of Health, Polymerase chain reaction, Safety, Infection, Biotechnology, CMS, NASDAQ, Vaccination, Securities Act of 1933, Trustee, Collection, LinkedIn, City University, Student, COVID-19 testing, Pharmaceutical industry, Vaccine, Applied Food Technologies

Through a partnership with Cleared4 software platform, ADCL provides a wide range of COVID-19 related health services to help CUNY mitigate COVID-19 associated risks.

Key Points: 
  • Through a partnership with Cleared4 software platform, ADCL provides a wide range of COVID-19 related health services to help CUNY mitigate COVID-19 associated risks.
  • Given our infrastructure and client concentration in New York City, we are pleased to continue servicing CUNY while we expand our test offering and services.
  • Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA").
  • Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA.